A systematic review of vinorelbine for the treatment of breast cancer

Breast Journal

Volumn 19, Issue 2, 2013, Pages 180-188

  Xu, Ying Chun ^a   Wang, Hong Xia ^a   Tang, Lei ^a   Ma, Yue ^a   Zhang, Feng Chun ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

breast cancer; chemotherapy; meta analysis; vinorelbine

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; NAVELBINE;

ADJUVANT THERAPY; ALOPECIA; ANEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84874670642     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12071     Document Type: Review

References (34)

1. Gregory RK, Smith IE,. Vinorelbine-a clinical review. Br J Cancer 2000; 82: 1907-13.
2. Colleoni M, Manente P, Stocker J, et al,. A randomized phase II trial of two different schedules of mitomycin C and vinorelbine in pretreated breast cancer. Oncology 1997; 54: 438-9.
3. Elomaa I, Joensuu H, Blomqvist C,. Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial. Ann Oncol 2003; 14: 699-703.
4. Coudert B, Focan C, Genet D, et al,. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int 2008; 25: 680-96.
5. Livi L, Paiar F, Santini R, et al,. Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer. Anticancer Drugs 2006; 17: 1081-5.
6. Lorusso V, Cinieri S, Giampaglia M, et al,. Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. Breast 2010; 19: 214-8.
7. Park IH, Ro J, Lee KS, et al,. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs 2010; 28: 659-69.
8. Gebbia V, Caruso M, Borsellino N, et al,. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM). Anticancer Res 2006; 26: 3143-50.
9. Keller AM, Mennel RG, Georgoulias VA, et al,. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893-901.
10. Costa SD, Loibl S, Kaufmann M, et al,. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 2010; 28: 83-91.
11. von Minckwitz G, Blohmer JU, Raab G, et al,. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al,. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.
13. Joensuu H, Bono P, Kataja V, et al,. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without Trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2006; 27: 5685-92.
14. Burstein HJ, Keshaviah A, Baron AD, et al,. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110: 965-72.
15. Redana S, Donadio M, Nolè F, et al,. Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer 2010; 10: 28.
16. Meier CR, Illiger HJ, Steder M, et al,. Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment. Onkologie 2008; 31: 447-53.
17. Pajka B, Cufera T, Canneyb P, et al,. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2008; 17: 180-5.
18. Verma S, Wong NS, Trudeau M, et al,. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol 2007; 30: 297-302.
19. Antonella Venturino 1, Danila Comandini 1, Carlotta Simoni 1, et al,. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin Breast Cancer Res Treat 2000; 60: 195-200.
20. Martin M, Ruiz A, Munoz M, et al,. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8: 219-25.
21. Kim MK, Kim SB, Ahn JH, et al,. Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients. Cancer Res Treat 2006; 38: 206-13.
22. Norris B, Pritchard KI, James K, et al,. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18: 2385-94.
23. Ejlertsen B, Mouridsen HT, Langkjer ST, et al,. Phase III Study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 22: 2313-20.
24. Frasci G, Cornelia P, Aiuto GD, et al,. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Ann Oncol 2000; 11: 367-71.
25. Blajman C, Balbiani L, Block J, et al,. A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-Fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 1999; 85: 1091-7.
26. Namer M, Soler-Michel P, Turpin F, et al,. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer 2001; 37: 1132-40.
27. Kerbrat P, Roche H, Bonneterre J, et al,. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. Br J Cancer 2007; 96: 1633-8.
28. Chua S, Smith IE, A'Hern RP, et al,. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol 2005; 16: 1435-41.
29. Von Minckwitz G, Kümmel S, Vogel P, et al,. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-51.
30. Elling D, Eggemann H, Kümmel S, et al,. Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. Breast 2003; 12: 208-11.
31. Riccardi A, Brugnatelli S, Danova M, et al,. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study. Tumori 2006; 92: 6-12.
32. Boccardo F, Rubagotti A, Guglielmini P, et al,. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Oncology No 15S 2010: 78: 274-81.
33. Domenech GH, Vogel CL,. A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2001; 2: 113-28.
34. Chan A,. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 2007; 18: 1152-8.